Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285298859> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4285298859 endingPage "125" @default.
- W4285298859 startingPage "121" @default.
- W4285298859 abstract "Objectives: To evaluate the relevance of non-bridging therapy with unfractionated heparin during the temporary, pre-procedural interruption of direct oral anticoagulants (DOACs) in patients with cancer-associated venous thromboembolism (VTE). Materials and Methods: This retrospective study included 142 patients with cancer and VTE who required temporary interruption of DOACs before invasive procedures. Data, including rates of VTE recurrence, non-major bleeding, and major bleeding, were compared between patients who received or not received alternative therapy with unfractionated heparin during interruption. Results: Sixty-eight patients were prescribed heparin, while 74 were not. There were no differences in age, body mass index, white blood cell count, hemoglobin level, or platelet count between the groups. VTE recurrence was observed in four (6%) and one (1%) patient in the heparin bridging and non-bridging groups, respectively (risk ratio [RR]: 4.4, 95% confidence interval [CI]: 0.50-38.0, p=0.19). Non-major bleeding occurred in three (4%) and two (3%) patients in the bridging and non-bridging groups (RR: 1.6, 95%CI: 0.28-9.48, p=0.67), while major bleeding occurred in 0 (0%) and three patients (4%) (p=0.25), respectively. Conclusion: Our findings confirm the relevance of non-bridging therapy with unfractionated heparin for reducing VTE risk during DOAC interruption in patients with cancer." @default.
- W4285298859 created "2022-07-14" @default.
- W4285298859 creator A5014886954 @default.
- W4285298859 creator A5027203076 @default.
- W4285298859 creator A5049038594 @default.
- W4285298859 creator A5074633498 @default.
- W4285298859 date "2022-06-25" @default.
- W4285298859 modified "2023-10-01" @default.
- W4285298859 title "Relevance of Non-Bridging Therapy with Heparin during Temporary Interruption of Direct Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism" @default.
- W4285298859 cites W1638546262 @default.
- W4285298859 cites W1837600385 @default.
- W4285298859 cites W1981210035 @default.
- W4285298859 cites W2018856451 @default.
- W4285298859 cites W2047235831 @default.
- W4285298859 cites W2134427191 @default.
- W4285298859 cites W2189476799 @default.
- W4285298859 cites W2792827296 @default.
- W4285298859 cites W2792857103 @default.
- W4285298859 cites W2891328972 @default.
- W4285298859 cites W2902233584 @default.
- W4285298859 cites W2973632923 @default.
- W4285298859 cites W2989714602 @default.
- W4285298859 cites W3000329838 @default.
- W4285298859 cites W3012340745 @default.
- W4285298859 cites W3119239593 @default.
- W4285298859 doi "https://doi.org/10.3400/avd.oa.22-00005" @default.
- W4285298859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35860816" @default.
- W4285298859 hasPublicationYear "2022" @default.
- W4285298859 type Work @default.
- W4285298859 citedByCount "1" @default.
- W4285298859 countsByYear W42852988592023 @default.
- W4285298859 crossrefType "journal-article" @default.
- W4285298859 hasAuthorship W4285298859A5014886954 @default.
- W4285298859 hasAuthorship W4285298859A5027203076 @default.
- W4285298859 hasAuthorship W4285298859A5049038594 @default.
- W4285298859 hasAuthorship W4285298859A5074633498 @default.
- W4285298859 hasBestOaLocation W42852988591 @default.
- W4285298859 hasConcept C126322002 @default.
- W4285298859 hasConcept C141071460 @default.
- W4285298859 hasConcept C174348530 @default.
- W4285298859 hasConcept C2777557582 @default.
- W4285298859 hasConcept C2780868729 @default.
- W4285298859 hasConcept C2991741193 @default.
- W4285298859 hasConcept C31258907 @default.
- W4285298859 hasConcept C41008148 @default.
- W4285298859 hasConcept C44249647 @default.
- W4285298859 hasConcept C71924100 @default.
- W4285298859 hasConcept C82789193 @default.
- W4285298859 hasConceptScore W4285298859C126322002 @default.
- W4285298859 hasConceptScore W4285298859C141071460 @default.
- W4285298859 hasConceptScore W4285298859C174348530 @default.
- W4285298859 hasConceptScore W4285298859C2777557582 @default.
- W4285298859 hasConceptScore W4285298859C2780868729 @default.
- W4285298859 hasConceptScore W4285298859C2991741193 @default.
- W4285298859 hasConceptScore W4285298859C31258907 @default.
- W4285298859 hasConceptScore W4285298859C41008148 @default.
- W4285298859 hasConceptScore W4285298859C44249647 @default.
- W4285298859 hasConceptScore W4285298859C71924100 @default.
- W4285298859 hasConceptScore W4285298859C82789193 @default.
- W4285298859 hasIssue "2" @default.
- W4285298859 hasLocation W42852988591 @default.
- W4285298859 hasLocation W42852988592 @default.
- W4285298859 hasLocation W42852988593 @default.
- W4285298859 hasOpenAccess W4285298859 @default.
- W4285298859 hasPrimaryLocation W42852988591 @default.
- W4285298859 hasRelatedWork W1986583373 @default.
- W4285298859 hasRelatedWork W2047967234 @default.
- W4285298859 hasRelatedWork W2145532404 @default.
- W4285298859 hasRelatedWork W2155855469 @default.
- W4285298859 hasRelatedWork W2331409909 @default.
- W4285298859 hasRelatedWork W2439875401 @default.
- W4285298859 hasRelatedWork W2885597621 @default.
- W4285298859 hasRelatedWork W2982059048 @default.
- W4285298859 hasRelatedWork W3000568411 @default.
- W4285298859 hasRelatedWork W4238549103 @default.
- W4285298859 hasVolume "15" @default.
- W4285298859 isParatext "false" @default.
- W4285298859 isRetracted "false" @default.
- W4285298859 workType "article" @default.